Case Study: AstraZeneca achieves faster delivery of life‑saving treatments with DocuSign eSignature

AstraZeneca Provides Life-Saving Treatments Faster with Docusign eSignature

AstraZeneca, the $26 billion biopharmaceutical with 57,000 employees, set out to “accelerate innovative science” by digitizing obsolete processes to bring treatments to market faster. The company needed a compliant, secure e‑signature solution that would win organizational buy‑in, so it began with a focused pilot to replace wet‑signed supplier request forms in procurement while validating FDA Part 11 and other regulatory requirements.

AstraZeneca implemented DocuSign eSignature with support from DocuSign’s CSA program and a Part 11 validation partner, then established a DocuSign Center of Excellence and trained dedicated roles to drive adoption. The rollout expanded to HR and sales, integrated via APIs, and delivered fast, measurable benefits: 85% of agreements now sign in less than one day, customer satisfaction rose 16%, critical system stability improved ~80%, and the company accelerated operations, reduced costs and compliance risk.

AstraZeneca

Dave Smoley

chief information officer